Navigation Links
Derma Sciences Announces 3-Year Licensing Deals for Highly Profitable Character Strip Bandages
Date:10/28/2008

roduct, MEDIHONEY(TM), is sold throughout the world by Derma Sciences and Comvita New Zealand -- the licensor of the patented honey-based technology -- and is the leading brand of honey-based dressings for the management of wounds and burns. The product has been shown to be effective in a variety of wounds and burns, and was recently the focus of a large-scale randomized controlled trial on leg ulcers. Derma has two products in development: the BIOGUARD(TM) line of barrier gauze dressings, and DSC127, the company's novel angiotensin analog for accelerated wound healing and scar reduction. The barrier technology was licensed from Quick-Med in Q1 of 2007 and is pending its initial FDA marketing clearance. DSC127 was licensed from The University of Southern California in Q4 of 2007 and is entering into a Phase II study, with anticipated initial patient enrollment to begin in Q3 of 2008. For more information about Derma Sciences, Inc., visit its home page on the Internet at http://www.dermasciences.com.

Contact: Derma Sciences, Inc. Allen & Caron Inc

Edward J. Quilty Rudy Barrio (US Investors)

Chairman and CEO r.barrio@allencaron.com

equilty@dermasciences.com

(609) 514-4744 Brian Kennedy (media)

brian@allencaron.com

(212) 691-8087


'/>"/>
SOURCE Derma Sciences, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related medicine news :

1. QUANTEL Intends to Strengthen its Dermatology/ Aesthetics Division With the Acquisition of WaveLight Aesthetic GmbH
2. Dermatologists identify North Texas leishmaniasis outbreak
3. Tissue-Growth Gene Tied to Scleroderma
4. American Academy of Dermatology Association Commends President Bush for Signing Tanning Accountability and Notification (TAN) Act
5. UltraShape(TM) Non-Invasive Fat Reduction and Body Contouring Clinical Study Results Presented at American Society for Dermatologic Surgery Annual Meeting
6. VivaScope(R) Confocal Imager May Eliminate Need for Routine Skin Biopsies for Dermatology Patients
7. Galderma Associates Itself to Cartiers Womens Initiative Awards to Recognize Female Entrepreneurs From Around the Globe
8. American Academy of Dermatology: New Study Finds Women More Likely Than Men to be Affected by Acne as Adults
9. New Study Provides Scientific Evidence That DermaLastyl Face Cream Reduces Wrinkles
10. Dermatologists Warn Fitness Enthusiasts: Dont Let Exercise-Related Skin Problems Outweigh the Benefits of Physical Activity
11. Active compounds found in Ganoderma lucidum fungus with potential to treat prostate cancer
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Medicine News(10 mins):Health News:Discovery Health's New Year, New You Week Brings Transformation and Inspiration to the Resolution Season 2Health News:Discovery Health's New Year, New You Week Brings Transformation and Inspiration to the Resolution Season 3Health News:Discovery Health's New Year, New You Week Brings Transformation and Inspiration to the Resolution Season 4Health News:Consumer Watchdog Releases Coercive Lobbying E-Mail to Employees of United Health Group, Calls It 'Political Harassment' of Workers 2Health News:Consumer Watchdog Releases Coercive Lobbying E-Mail to Employees of United Health Group, Calls It 'Political Harassment' of Workers 3Health News:Consumer Watchdog Releases Coercive Lobbying E-Mail to Employees of United Health Group, Calls It 'Political Harassment' of Workers 4Health News:Jefferson neurosurgeon helps draft new treatment guidelines for brain metastases 2Health News:Prize4Life and the Jackson Laboratory team up to fight ALS 2Health News:Prize4Life and the Jackson Laboratory team up to fight ALS 3Health News:New Report Examines the Role of Communications Technologies in Humanitarian Crises, 2Health News:New Report Examines the Role of Communications Technologies in Humanitarian Crises, 3Health News:New Report Examines the Role of Communications Technologies in Humanitarian Crises, 4
Other Medicine News:Health News:Mars First Confectionery Company to Launch Front-of-Pack Nutrition Labeling Globally 2Health News:Mars First Confectionery Company to Launch Front-of-Pack Nutrition Labeling Globally 3Health News:Mars First Confectionery Company to Launch Front-of-Pack Nutrition Labeling Globally 4Health News:Mars First Confectionery Company to Launch Front-of-Pack Nutrition Labeling Globally 5Health News:Sun Safety Champions Team Up With LPGA Tour Pro Paula Creamer 2Health News:Sun Safety Champions Team Up With LPGA Tour Pro Paula Creamer 3Health News:Sun Safety Champions Team Up With LPGA Tour Pro Paula Creamer 4Health News:GBH Communications, Inc. Offers Next Generation of LifeSize High Definition Video Communications and Telepresence Products 2Health News:GBH Communications, Inc. Offers Next Generation of LifeSize High Definition Video Communications and Telepresence Products 3Health News:MyHealthGate, Inc. Joins With LiveActive Chewy Granola Bars to Raise Digestive Health Awareness 2Health News:Social Security 2009 COLA Helps, But People with Disabilities Will Still Struggle, Says Allsup 2Health News:Social Security 2009 COLA Helps, But People with Disabilities Will Still Struggle, Says Allsup 3Health News:Social Security 2009 COLA Helps, But People with Disabilities Will Still Struggle, Says Allsup 4Health News:Social Security 2009 COLA Helps, But People with Disabilities Will Still Struggle, Says Allsup 5Health News:Social Security 2009 COLA Helps, But People with Disabilities Will Still Struggle, Says Allsup 6Health News:Social Security 2009 COLA Helps, But People with Disabilities Will Still Struggle, Says Allsup 7Health News:Women's Contraceptive Perceptions and Realities Don't Match Up 2Health News:Women's Contraceptive Perceptions and Realities Don't Match Up 3Health News:Women's Contraceptive Perceptions and Realities Don't Match Up 4
Breaking Medicine Technology:China Yongxin Pharmaceuticals, Inc. Announces Results for the Third Quarter Ended September 30, 2009 2China Yongxin Pharmaceuticals, Inc. Announces Results for the Third Quarter Ended September 30, 2009 3China Yongxin Pharmaceuticals, Inc. Announces Results for the Third Quarter Ended September 30, 2009 4China Yongxin Pharmaceuticals, Inc. Announces Results for the Third Quarter Ended September 30, 2009 5China Yongxin Pharmaceuticals, Inc. Announces Results for the Third Quarter Ended September 30, 2009 6China Yongxin Pharmaceuticals, Inc. Announces Results for the Third Quarter Ended September 30, 2009 7China Yongxin Pharmaceuticals, Inc. Announces Results for the Third Quarter Ended September 30, 2009 8OrBIT Study Long Term Results Show Sustained Therapeutic Effect of Percutaneous Tibial Nerve Stimulation at 12 Months 2OrBIT Study Long Term Results Show Sustained Therapeutic Effect of Percutaneous Tibial Nerve Stimulation at 12 Months 3OrBIT Study Long Term Results Show Sustained Therapeutic Effect of Percutaneous Tibial Nerve Stimulation at 12 Months 4WorldHeart Receives US Clinical Study Approval for the Levacor 28TM 29 VAD 4876 1WorldHeart Receives US Clinical Study Approval for the Levacor 28TM 29 VAD 4876 2WorldHeart Receives US Clinical Study Approval for the Levacor 28TM 29 VAD 4876 3Diabetes drug linked to increased risk of heart failure 54955 1Diabetes drug linked to increased risk of heart failure 54955 2Type 1 diabetes linked to immune response to wheat 54951 1Type 1 diabetes linked to immune response to wheat 54951 2
Other Medicine Technology:Alpharma Presents Data Addressing Abuse Liability Features, Safety and Efficacy on ALO-01 (EMBEDA(TM)) (morphine sulfate extended-release with sequestered naltrexone hydrochloride) at the American Pain Society Annual Scientific Session 2Alpharma Presents Data Addressing Abuse Liability Features, Safety and Efficacy on ALO-01 (EMBEDA(TM)) (morphine sulfate extended-release with sequestered naltrexone hydrochloride) at the American Pain Society Annual Scientific Session 3Alpharma Presents Data Addressing Abuse Liability Features, Safety and Efficacy on ALO-01 (EMBEDA(TM)) (morphine sulfate extended-release with sequestered naltrexone hydrochloride) at the American Pain Society Annual Scientific Session 4Alpharma Presents Data Addressing Abuse Liability Features, Safety and Efficacy on ALO-01 (EMBEDA(TM)) (morphine sulfate extended-release with sequestered naltrexone hydrochloride) at the American Pain Society Annual Scientific Session 5Alpharma Presents Data Addressing Abuse Liability Features, Safety and Efficacy on ALO-01 (EMBEDA(TM)) (morphine sulfate extended-release with sequestered naltrexone hydrochloride) at the American Pain Society Annual Scientific Session 6Alpharma Presents Data Addressing Abuse Liability Features, Safety and Efficacy on ALO-01 (EMBEDA(TM)) (morphine sulfate extended-release with sequestered naltrexone hydrochloride) at the American Pain Society Annual Scientific Session 7Data from Randomized Pilot Study, Real-World Use of OrbusNeich's Genous(TM) Bio-engineered R stent(TM) to be Presented in Symposium at EuroPCR 2008 2